Table 3.
Outcomes of Patients in Complete Cytogenetic Response by Increased Level of Detectable BCR-ABL1 Transcripts33
| Follow-up From QPCR Increase (Months) | |||||
|---|---|---|---|---|---|
| QPCR Log Increase | Number of Patients | Imatinib Dose Escalation | CML Progression | Median | Range |
| Persistent MMR | |||||
| Any | 28 | 0 | 0 | 36 | 3–62 |
| Loss of MMR | |||||
| >0.5 to 1 | 12 | 0 | 0 | 34 | 14–59 |
| >1 to 2 | 25 | 0 | 2 | 31 | 6–52 |
| >2 | 11 | 4 | 4 | 45 | 20–57 |
| Not in MMR | |||||
| <1 | 32 | 3 | 1 | 35 | 10–70 |
| >1 | 8 | 1 | 4 | 25 | 12–56 |
QPCR indicates quantitative polymerase chain reaction; CML, chronic myeloid leukemia; MMR, major molecular response.